KaJ Labs Locks 100 Million Lithosphere (LITHO) Tokens Until 2035 to Boost Network Security and Stability
Seattle, Washington–(Newsfile Corp. – March 7, 2023) – KaJ Labs, a leading blockchain-based firm and…
Seattle, Washington–(Newsfile Corp. – March 7, 2023) – KaJ Labs, a leading blockchain-based firm and…
Toyota City, Japan, Mar 7, 2023 – (JCN Newswire) – TOYOTA GAZOO Racing begins its…
DUBAI, UAE, Mar 7, 2023 – (ACN Newswire) – Crypto Oasis, the fastest growing WEB3…
LONDON, Mar 7, 2023 – (ACN Newswire) – HotelRunner, the leading accommodation and travel technologies…
RICHMOND, Va.–(BUSINESS WIRE)–Kinsale Capital Group, Inc. (NYSE: KNSL) announced the following promotions, effective March 1,…
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Alight, Inc. (“Alight” or the “Company”) (NYSE: ALIT), a leading cloud-based human capital…
2022 Highlights Full year 2022 revenue of $408.5 million, up 20.0% year-over-year. Full year 2022…
DALLAS–(BUSINESS WIRE)–Mr. Cooper Group Inc. (NASDAQ: COOP) announced two executive leadership appointments today – the…
PEARL RIVER, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction…
LONDON, UK / March 7, 2023 – Egress, a cybersecurity company that provides intelligent email…
Topline pivotal Phase 3 results expected during second half of 2023 Potential new treatment option…
OXFORD, England, March 07, 2023 (GLOBE NEWSWIRE) — MitoRx Therapeutics (MitoRx), a biotechnology company developing…
GÉNOMIQUE | THÉRAPIES CELLULAIRES & GÉNIQUES | BIOPRODUCTION Genomic Vision lance FiberSmart®, un logiciel fondé…
WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) — Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader…
Oversubscribed financing to support continued development of its diversified pipeline focused on central nervous system…
Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong…
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today…
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted…
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by…
Quickly identify, assess, prioritize and remediate security risks and vulnerabilities with a fully customizable solution…